Used primarily in the pharmaceutical industry as a key intermediate in the synthesis of phosphodiesterase type 5 (PDE5) inhibitors, particularly in the production of drugs for erectile dysfunction and pulmonary arterial hypertension. Its structure enables selective binding and inhibition of PDE5, enhancing nitric oxide effects by increasing cyclic guanosine monophosphate (cGMP) levels in smooth muscle cells. This leads to vasodilation and improved blood flow. Due to its efficacy and specificity, it is a critical building block in the development of potent and selective therapeutic agents targeting PDE5-related conditions.